Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780313 | 1.00 | MMP8 (0.50) | MMP8GAAPIN1KMT2AMEN1 | |
| SCHEMBL23688603 | 0.85 | CYP2C19 (0.65) | MMP8GAAPIN1KMT2AMEN1 | |
| SCHEMBL8669701 | 0.85 | CYP2C19 (0.65) | MMP8GAAPIN1KMT2AMEN1 | |
| SCHEMBL23688606 | 0.85 | CYP2C19 (0.65) | MMP8GAAPIN1KMT2AMEN1 | |
| SCHEMBL10165351 | 0.85 | KMT2A (0.46) | MMP8GAAKMT2AMEN1CYP2C19 | |
| SCHEMBL3168058 | 0.85 | KMT2A (0.59) | MMP8GAAKMT2AMEN1CYP2C19 | |
| SCHEMBL20274587 | 0.85 | KMT2A (0.59) | MMP8GAAKMT2AMEN1CYP2C19 | |
| SCHEMBL5099068 | 0.84 | TDP1 (0.41) | MMP8GAANPC1CYP2C19SMN1; SMN2 | |
| SCHEMBL23535218 | 0.84 | L3MBTL1 (0.45) | GAAKMT2ACYP2C19SMN1; SMN2KDM4E | |
| SCHEMBL27587299 | 0.84 | MMP8 (0.48) | MMP8GAAPIN1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-115838530-A | Modified PET composite material and preparation method thereof | 河北华密新材科技股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20060252093-A1 | Heterocyclic organic molecules through intramolecular formation of n-acyliminium ions | CARLSBERG A/S (DK) | 2006-11-09 | — | — | US | disclosed |
| US-4205000-A | Dibenzo-oxa-bicyclonona-2,6-dienes | THE UNIVERSITY OF ILLINOIS FOUNDATION (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | MMP8 3116/4885GAA 2385/4885PIN1 4193/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | MMP8 26/4885GAA 352/4885PIN1 295/4885 |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | MMP8 3116/4885GAA 2385/4885PIN1 4193/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP8 26/4885GAA 352/4885PIN1 295/4885 |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | MMP8 3116/4885GAA 2385/4885PIN1 4193/4885 |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | MMP8 3116/4885GAA 2385/4885PIN1 4193/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP8 26/4885GAA 352/4885PIN1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.